focus -WSS

focus

author：hotspot 2025-09-27 14:10:35 - browse：386

ESMO signage in Madrid. — At ESMO 2023, antibody-drug conjugates were featured prominently. Andrew Joseph/STAT

MADRID — If you had to pinpoint one subject that stood out at this year’s European Society for Medical Oncology meeting, a massive conference with thousands of people from 140-some countries and 2,500 studies presented, it would be a burgeoning type of cancer treatment called antibody-drug conjugates.

The conference opened to the news that Merck had signed one of the biggest licensing deals in industry history — worth up to $22 billion — to partner on three of the compounds from ADC specialist Daiichi Sankyo. GSK followed up with an ADC licensing announcement of its own (if a much smaller one). Multiple ADC studies were presented at the meeting’s top sessions. ADCs were, in short, the belle of the cancer research ball.

The thing is, ADCs are actually quite an old approach.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Connecting traumatic brain injury and domestic violence

knowledge

hotspot

knowledge

WSS

A new study asks: Are we harming blood donors by taking blood?

Doctor appointment wait times are getting worse

Grail is spending more than ever lobbying Congress

Experimental asthma app from Apple and Anthem shows promise

Publishing genetic code of viruses could cause disaster

Readout Newsletter: Zepbound, Valneva's vaccine, and more

explore

focus

focus

At least 13 dead in Texas as scorching temps continue

Did the public have the right to know Arthur Ashe had AIDS?

Wildfire smoke exposes gaps in outdoor worker protections

Cancer diagnosis changes perspective doctor, former hospital CEO

After affirmative action ruling, medical educators look to 'holistic review'

What health policies could hitch a ride on a spending bill?

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Hollywood unions extend contract negotiations for actors

White House drug czar issues call for 'recovery

hotspot

Experimental asthma app from Apple and Anthem shows promise

Study suggests Covid rebound is far more common with Paxlovid than without

How state and local governments are sidelining science

NIH chief: government has fallen behind pharma on clinical trials

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

Listen: PBM conflicts, RSV vaccines, & the future of flu season

knowledge

hotspot

knowledge

explore